Month: March 2022

Old National Bancorp Announces Preferred Stock Quarterly Cash Dividend

Written by Customer Service on March 23, 2022. Posted in Dividend Reports And Estimates.

EVANSVILLE, Ind., March 23, 2022 (GLOBE NEWSWIRE) — Old National Bancorp (“Old National”) (NASDAQ: ONB) today announced that its Board of Directors declared a quarterly cash dividend of $17.50 per share (equivalent to $0.4375 per depositary share or 1/40th interest per share) on Old National’s 7.0% Fixed Rate Non-Cumulative Perpetual Preferred Stock, Series A (NASDAQ: ONBPP) and Series C (NASDAQ: ONBPO). The dividends are payable on May 20, 2022, to stockholders of record as of the close of business on May 5, 2022. About Old National Old National Bancorp (NASDAQ: ONB), the holding company of Old National Bank, is the largest bank holding company headquartered in Indiana. With more than $46 billion of assets and $34 billion of assets under management, it ranks among the top 35 banking companies based in the U.S. and has been recognized...

Homology Medicines Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights

Written by Customer Service on March 23, 2022. Posted in Earnings Releases And Operating Results.

– Formed New AAV Manufacturing and Innovation Business with Oxford Biomedica to Leverage Homology’s Process Development and Manufacturing Capabilities – – Received $130 Million Non-Dilutive Capital that Significantly Extends Cash Runway – – Launched pheEDIT Gene Editing Trial for PKU and juMPStart Gene Therapy Trial for Hunter Syndrome; Program Updates Expected by Year-End – – Company Updates Guidance on pheNIX Gene Therapy Trial for PKU – BEDFORD, Mass., March 23, 2022 (GLOBE NEWSWIRE) — Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today financial results for the fourth quarter and full year ended December 31, 2021, and highlighted recent accomplishments. “We recently closed our deal with Oxford Biomedica to form a new company that incorporates...

Karat Packaging Reports Fourth Quarter and Full Year 2021 Financial Results

Written by Customer Service on March 23, 2022. Posted in Earnings Releases And Operating Results.

– Fourth Quarter Net Sales Grew Nearly 30 Percent;Net Income Increased More than Three-Fold – CHINO, Calif., March 23, 2022 (GLOBE NEWSWIRE) — Karat Packaging Inc. (Nasdaq: KRT) (“Karat”), a specialty distributor and manufacturer of environmentally friendly, disposable foodservice products and related items, today announced financial results for the fourth quarter and full year ended December 31, 2021. Fourth Quarter 2021 HighlightsNet sales of $91.3 million, up 29.8 percent from the prior-year quarter. Gross profit of $28.3 million, up 46.7 percent from the prior-year quarter. Gross margin of 31.0 percent, an improvement of 360 basis points over the prior-year quarter. Net income of $6.0 million, up more than three-fold over the prior-year quarter. Net income margin of 6.5 percent, an improvement of 420 basis points over the...

Sientra Reports Record Plastic Surgery Revenue for Both Fourth Quarter and Full Year 2021

Written by Customer Service on March 23, 2022. Posted in Earnings Releases And Operating Results.

Sixth Consecutive Quarter of Record Growth Doubled Augmentation and Reconstruction Market Share Since 2019 Broadened Market Opportunity with Addition of Novel, FDA-Cleared Fat Grafting Technology SANTA BARBARA, Calif., March 23, 2022 (GLOBE NEWSWIRE) — Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company focused on enhancing lives by advancing the art of plastic surgery, today announced its financial results for the fourth quarter and full year ended December 31, 2021. Q4 and Full Year 2021 Financial HighlightsNet sales of $22.6 million, representing growth of 26.6% over the fourth quarter of 2020, excluding discontinued operations. Net sales of $80.7 million, representing growth of 47% over the full year 2020, excluding discontinued operations. Cash of $51.8 million as of December 31, 2021.Business...

Oil-Dri Announces Appointment of Patrick J. Walsh as New Vice President, Human Resources and Declares Quarterly Dividends

Written by Customer Service on March 23, 2022. Posted in Dividend Reports And Estimates.

CHICAGO, March 23, 2022 (GLOBE NEWSWIRE) — Oil-Dri Corporation of America (NYSE: ODC) announced that the Board of Directors appointed Patrick J. Walsh as Vice President, Human Resources effective March 21, 2022. Mr. Walsh will report directly to Daniel S. Jaffee, Oil-Dri’s President and Chief Executive Officer. Mr. Walsh will assume the responsibility of overseeing all the human resource functions across the organization. “We are pleased to welcome Patrick to Oil-Dri,” said Daniel S. Jaffee. “Patrick brings a wealth of experience in human capital management, strategy, and development. He will be a critical partner as we grow our team both domestically and globally. His appointment demonstrates our commitment to attracting and retaining top talent while maintaining our focus on ethics and culture.” Mr. Walsh was previously with...

NextNav Inc. Reports Fourth Quarter and Full Year 2021 Results

Written by Customer Service on March 23, 2022. Posted in Earnings Releases And Operating Results.

Launched Commercial Service for First Responders with FirstNet by AT&T and Signed Milestone Agreement with a Nationwide Carrier for E911 Ended Year with a Strong Balance Sheet Including No Debt and $100 Million in Cash Signed Important Platform Agreements in Full Year 2021, Resulting in $2.4 Million in Customer Billings MCLEAN, Va., March 23, 2022 (GLOBE NEWSWIRE) — NextNav Inc. (NASDAQ: NN) (“NextNav” or the “Company”), a leader in next generation GPS and 3D geolocation, today reported financial results for NextNav’s fourth quarter and full year ended December 31, 2021. Ganesh Pattabiraman, NextNav Co-founder and CEO, stated, “It was an exciting year for NextNav, capped off by the completion of our business combination with Spartacus Acquisition Corp., and continued execution against our strategic growth initiatives. We signed...

Phunware Reports Preliminary Full Year 2021 Financial Results

Written by Customer Service on March 23, 2022. Posted in Earnings Releases And Operating Results.

AUSTIN, Texas, March 23, 2022 (GLOBE NEWSWIRE) — Phunware, Inc. (NASDAQ: PHUN) (“Phunware” or “the Company”), a fully-integrated enterprise cloud platform for mobile that provides products, solutions, data and services for brands worldwide, today announced preliminary financial results for the year ended December 31, 2021. “The past year was an incredibly pivotal period for Phunware, as we made significant progress across all key segments of our business,” said Alan S. Knitowski, President, CEO and Co-Founder of Phunware. “The combination of our direct and indirect go-to-market strategies came to fruition in conjunction with the re-opening of the post-pandemic economy, resulting in extremely promising opportunities for our core MaaS business. Additionally, the acquisition of Lyte Technology late last year not only materially added...

Mustang Bio Reports Full-Year 2021 Financial Results and Recent Corporate Highlights

Written by Customer Service on March 23, 2022. Posted in Earnings Releases And Operating Results.

WORCESTER, Mass., March 23, 2022 (GLOBE NEWSWIRE) — Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced financial results and recent corporate highlights for the full year ended December 31, 2021. Manuel Litchman, M.D., President and Chief Executive Officer of Mustang, said, “In 2021, we continued to make great strides in advancing our cell and gene therapy programs. Notably, the U.S. Food and Drug Administration (“FDA”) approved two Mustang Investigational New Drug (“IND”) applications, the first to initiate a pivotal multicenter Phase 2 clinical trial to evaluate MB-107, a lentiviral gene therapy for the treatment...

Ollie’s Bargain Outlet Holdings, Inc. Reports Fourth Quarter and Fiscal 2021 Financial Results

Written by Customer Service on March 23, 2022. Posted in Earnings Releases And Operating Results.

~ Company Exceeds EPS Expectations ~ ~ Initiates Fiscal 2022 Guidance ~ HARRISBURG, Pa., March 23, 2022 (GLOBE NEWSWIRE) — Ollie’s Bargain Outlet Holdings, Inc. (NASDAQ: OLLI) (the “Company”) today reported financial results for the fourth quarter and full-year fiscal 2021. Fourth Quarter Summary: Total net sales decreased 2.8% to $501.1 million. Comparable store sales decreased 10.5% from the prior year increase of 8.8%. Comparable store sales decreased 2.0% compared with the fourth quarter of fiscal 2019. The Company opened five new stores, ending the quarter with 431 stores in 29 states, a year-over-year increase in store count of 11.1%. Operating income decreased 32.2% to $57.5 million. Adjusted operating income(1) decreased 32.1% to $57.3 million and adjusted operating margin(1) decreased 500 basis points to 11.4%. Net...

Reneo Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

Written by Customer Service on March 23, 2022. Posted in Earnings Releases And Operating Results.

IRVINE, Calif., March 23, 2022 (GLOBE NEWSWIRE) — Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the quarter and year ended December 31, 2021 and provided a business update. 2021 HighlightsRaised gross proceeds of $94 million in an initial public offering (IPO); cash runway sufficient to fund planned operations into 2024 Fast Track Designation granted in the U.S. for REN001 in primary mitochondrial myopathy (PMM) Initiated enrollment of STRIDE, a global, double-blind, randomized, placebo-controlled Phase 2b clinical trial of REN001 in patients with PMM Initiated STRIDE AHEAD, an open-label extension safety trial of REN001 in patients with...

Month: March 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals